knowledge -WSS

knowledge

author：entertainment 2025-08-11 11:45:57 - browse：15

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA sets aggressive timeline for overhauling inspection procedures

focus

WSS

Medicare drug price lawsuits could be good politics for Biden

Medicare Advantage coverage denials need scrutiny, senators say

Gene therapy denied for Afghan refugee whose father aided U.S.

At JPM 2024, hospital systems pitch financial strength to investors

Update the Apgar Score to remove skin color

FDA early review: GLP

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Novavax promises a turnaround & Lilly roils the obesity market

Prior authorization reform is both possible and imperative

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Maisha Meds is a PBM, but don't call it that

In age of alternative facts, a scholarly course on calling out crap

HPV vaccine, cervical cancer study delivers historic results

Novavax promises a turnaround & Lilly roils the obesity market

Dog Aging Project founders on what lies ahead after losing funding

Alkermes shareholders re

Nonprofit, backed by Microsoft, to certify AI tools in health care

focus

Profiling embryos to choose those with higher IQs is almost a reality

At JPM 2024, hospital systems pitch financial strength to investors

Dog Aging Project founders on what lies ahead after losing funding

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Flu vaccine reformulation won't be easy, manufacturers warn

Nonprofit, backed by Microsoft, to certify AI tools in health care

focus

focus

entertainment

hotspot